Published in final edited form as:

Cancer Res. 2014 April 1; 74(7): 1895–1901. doi:10.1158/0008-5472.CAN-13-2892.

A common cancer-associated DNA polymerase ϵ mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading

Daniel P. Kane and Polina V. Shcherbakova

Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska

Abstract

Exonucleolytic proofreading and DNA mismatch repair (MMR) act in series to maintain high-fidelity DNA replication and avoid mutagenesis. MMR defects elevate the overall mutation rate and are associated with increased cancer incidence. Hypermutable colorectal and endometrial tumors with functional MMR were recently reported to carry amino acid substitutions in the exonuclease domain of DNA polymerase ϵ (Pol ϵ). This created a notion that loss of the proofreading activity of Pol ϵ is an initiating cause of some sporadic human cancers. In this study, we identified a somatic P286R substitution in the conserved ExoI motif of Pol ϵ in a collection of 52 sporadic colorectal tumor specimens. This change has been repeatedly observed in colorectal and endometrial tumors in previous studies despite many possible ways to inactivate Pol ϵ proofreading. To understand the reasons for the recurrent appearance of the P286R variant, we characterized its functional consequences using the yeast model system. An analogous substitution in the yeast Pol ϵ produced an unusually strong mutator phenotype exceeding that of proofreading-deficient mutants by two orders of magnitude. This argues that the P286R mutation acts at some level other than loss of exonuclease to elevate cancer risk. Heterozygosity for the variant allele caused a strong mutator effect comparable to that of complete MMR deficiency, providing an explanation for why loss of heterozygosity is not required for the development of Pol ϵ -mutant human tumors.

Keywords

DNA polymerase ϵ ; cancer; mutator; proofreading; LOH

Introduction

Cancer cells contain thousands of mutations not present in normal cells. Changes in oncogenes and tumor suppressor genes directly promote carcinogenesis. In addition, the genomic instability leads to a genetic heterogeneity of tumors, contributing to their ability to adapt and develop resistance to therapy (1). For most cancers, the mechanisms underlying

---

Corresponding author: Polina Shcherbakova, 986805 Nebraska Medical Center, Omaha, NE 68198. Phone: 402-559-7694; Fax: 402-559-4651; pshcherb@unmc.edu.

The authors disclose no potential conflicts of interest.

the high frequency of genetic changes are unknown. Maintenance of the low mutation rate relies heavily on three DNA replication fidelity mechanisms: (i) accurate nucleotide selection by the replicative DNA polymerases α , δ and ϵ , (ii) proofreading of errors by the 3'-exonuclease activity of Pol δ and Pol ϵ , and (iii) correction of mispairs by the DNA mismatch repair (MMR) system. These processes act in series keeping the mutation rate per cell division at a low level of less than 10^{-10} . Defects in any of the three mechanisms accelerate tumorigenesis in mice (2, 3), and inherited mutations in the human MMR genes cause predisposition to colorectal cancer (CRC) in Lynch syndrome (4). The MMR gene *MLH1* is also somatically inactivated in $\sim 12\%$ of sporadic CRC.

A recent large-scale molecular characterization of sporadic CRC revealed that although MMR-deficient cancers are hypermutated, tumors with the highest mutational load had alterations in Pol ϵ rather than MMR defects (5). Similarly, hypermutated sporadic endometrial tumors frequently contained Pol ϵ alterations (6, 7). In both cases, the changes affected conserved amino acid residues in the exonuclease domain, suggesting that inactivation of exonuclease activity was responsible for the hypermutator phenotype. Additionally, germline mutations affecting the exonuclease domains of Pol ϵ and Pol δ were found to cause a high-penetrance hereditary CRC predisposition (8). These discoveries strongly suggested that loss of proofreading activity of replicative DNA polymerases is the initiating cause of some hereditary and sporadic human cancers.

In this work, we assessed the status of the exonuclease domain of Pol ϵ in sporadic colon and rectum adenocarcinomas from 52 patients undergoing treatment at the University of Nebraska Medical Center (UNMC). We identified a P286R substitution in the conserved ExoI motif essential for the proofreading activity. This change was observed previously in two other colon tumors (9) and 14 endometrial tumors (6, 7) and is by far the most frequent somatic Pol ϵ mutation in both types of cancer. The same mutation was found in a colon carcinoma cell line HCC2998 (10). A P286H substitution was reported in one additional colon tumor (5), and a germline mutation of the homologous Pro327 in Pol δ was present in a patient with a family history of CRC (8). The repetitive occurrence of changes at this proline was surprising, because studies in model organisms have demonstrated that proofreading can be inactivated by altering a variety of amino acid residues in the exonuclease domain (11-13). To gain insight into the unique properties of the P286R variant, we studied its genome-destabilizing potential in the yeast model system using several mutational assays. The corresponding P301R change in yeast Pol ϵ conferred an exceptionally strong mutator phenotype greatly exceeding that of any previously characterized Pol ϵ mutant, including proofreading-deficient mutants. Moreover, in contrast to mutations inactivating the exonuclease of Pol ϵ , which barely affect the mutation rate in the heterozygous state, heterozygosity for the P301R produced a strong mutator effect comparable to that of MMR deficiency. The results (i) suggest that the extraordinary mutagenic potential of this Pol ϵ variant results from functional defects distinct from loss of proofreading; (ii) explain earlier observations that loss of heterozygosity for the *POLE-P286R* mutation is not required for tumor development; and (iii) advocate an idea that the frequent occurrence of P286R in sporadic tumors is related to its stronger mutator effect in comparison to other exonuclease domain changes and the resulting greater chance of accumulating cancer-driving mutations.

Materials and Methods

Snap-frozen colon and rectum adenocarcinoma tissue and matching normal mucosa were obtained from the UNMC Tissue Procurement Shared Resource. The study was approved by the UNMC Institutional Review Board. Exons 7-16 of *POLE* (or all coding exons for the tumor carrying P286R) were amplified by PCR using DNA isolated from the tissue (Supplementary Fig. S1 and Table S1) and Sanger-sequenced.

Yeast strains used in the study (Supplementary Table S2) are isogenic to E134 (14). Diploids contain the *Kluyveromyces lactis* *LEU2* gene 26 nucleotides downstream of *CAN1* in one copy of chromosome *V* and a deletion of *CAN1* in the homologous chromosome, allowing for selection of recessive *can1* mutants on medium containing canavanine and lacking leucine. To replace the chromosomal *POL2* with the *pol2-P301R* allele, an integrative plasmid YIpDK1 was constructed by cloning a 2.1 kb *HpaI-EcoRI* *POL2* fragment into *NruI* and *EcoRI* sites of YIp5 (15). The *pol2-P301R* mutation was created in YIpDK1 by site-directed mutagenesis. The spontaneous mutation rate was measured by fluctuation analysis as described (14).

Results and Discussion

Inspired by the association of Pol ϵ exonuclease domain mutations with intestinal cancer in mice (2) and humans (5, 8, 9), we began this study by analyzing this region of Pol ϵ in 52 sporadic CRC patients treated at UNMC. The age distribution of the patients and the anatomical site of the tumor are listed in Table 1. Ten of the 52 tumors carried a common variant allele producing an Ala252Val change in Pol ϵ (nine in heterozygous and one in homozygous state; Table 1). The variant allele frequency did not differ significantly ($p=0.11$; Chi-square) from that reported for the general population (16). One tumor carried an Arg259His variant, also observed previously in the general population (allele frequency 0.5-1%). Remarkably, one tumor (T-04-364) had a heterozygous mutation leading to a P286R substitution in the ExoI motif (Table 1; Fig. 1). This change was not present in the publicly available databases of common polymorphisms, but was reported previously as a somatic mutation in 16 other sporadic cancer cases (6, 7, 9) and as a potential cancer-specific variant in a colon carcinoma cell line HCC2998 (10). Other mutations affecting Pro286 in Pol ϵ or a homologous Pro327 in Pol δ were also observed in CRC patients (5, 8). The P286R change found in tumor T-04-364 was not present in normal cells of the patient (Fig. 1A), indicating that it was a somatic mutation. The recurrent emergence of Pro286 alterations is in sharp contrast to the apparently random incidence in tumors of other changes in the exonuclease domain of Pol ϵ , most of which were only observed once (5-7, 9).

Pro286 is located at the end of the ExoI motif several amino acids downstream of the carboxylate residues Asp275 and Glu277 essential for catalysis of the exonuclease reaction (Fig. 1B). Mutations affecting these carboxylates abolish the exonuclease activity of Pol ϵ (15), and so do analogous mutations in other proofreading exonucleases (13). In addition, multiple other amino acid residues in the exonuclease domain, including those in the conserved motifs ExoII and ExoIII, are known to be essential for proofreading (11-13). To understand why the P286R variant is uniquely observed at a high frequency in tumors, we

examined its effects on mutagenesis using the yeast *S. cerevisiae* model system. Haploid and diploid strains with the corresponding *pol2-P301R* allele were constructed, and mutagenesis was measured at three different reporter loci (Table 2). The Can^r forward mutation assay scores a variety of base substitutions, frameshifts and larger rearrangements that inactivate the *CAN1* gene. The *lys2-InsE_{A14}* and *his7-2* reporters are frameshift alleles that revert to wild type predominantly via -1 and +1 events, respectively. In haploid *pol2-P301R* mutants, the rate of Can^r, Lys⁺ and His⁺ events was increased 150-fold, 44-fold and 370-fold, respectively, in comparison to the wild-type strain. Strikingly, for all three markers, the mutator effect of *pol2-P301R* was ~50-fold higher than that of the *pol2-4* mutation inactivating Polε proofreading due to the replacement of both catalytic carboxylates at the ExoI motif with alanines (15). Thus, despite the location of Pro286/301 in the ExoI motif, its alteration results in fidelity defects substantially more severe than disruption of proofreading. Moreover, the mutator effect of *pol2-P301R* greatly exceeded that of any previously characterized Polε mutant, including mutants with strongly impaired nucleotide selectivity (Fig. 2).

The mutant *POLE* alleles were always found in the heterozygous state in sporadic human tumors ((5, 6, 9); Fig. 1A). Diploid yeast strains heterozygous for the *pol2-P301R* showed a remarkable increase in the rate of Can^r mutation and *his7-2* reversion (27-fold and 29-fold, respectively; Table 2). This is drastically different from strains heterozygous for the *pol2-4* mutation inactivating proofreading that showed only a 2.2-fold elevated Can^r mutation and 3.8-fold elevated *his7-2* reversion. The Can^r mutation rate in the *POL2/pol2-P301R* heterozygotes was comparable to that in strains with completely inactivated MMR, which is a well-known cancer-driving replication fidelity defect. For example, the haploid *mlh1* strain is a 26-fold mutator (14). This suggests that heterozygosity for the *POLE-P286R* seen in tumors can have a potent genome-destabilizing effect and explain the hypermutated phenotype of these tumors. Diploid yeast homozygous for the *pol2-P301R* allele showed extreme hypermutability (a 740-fold, 280-fold and 1600-fold increase in the rate of Can^r, Lys⁺ and His⁺ events; Table 2). The dramatic difference in the apparent mutation rate between diploids and haploids is commonly observed when the mutation load approaches a lethal threshold. It is explained by death in haploids of a fraction of cells with the highest level of mutagenesis that survives and produces the majority of mutants in diploids ((17-19) and references therein). In contrast, the *pol2-4/pol2-4* diploids are only slightly more mutable than *pol2-4* haploids ((19) and Table 2), consistent with a modest level of replication errors and fewer cells accumulating lethal mutations. This further emphasizes the differences between the mutator effects of *pol2-P301R* and the proofreading deficiency.

Due to the location of cancer-associated Polε changes at conserved residues in the exonuclease domain, a concept has formed in the past year that loss of Polε proofreading is responsible for the development of hypermutated human tumors. The functional consequences of the Polε variants found in cancers, however, have not been tested previously. The studies described here indicate that the P286R variant confers fidelity defects well beyond those expected from proofreading deficiency. Pro286 is conserved in a B-family polymerase ζ lacking proofreading activity (Fig. 1B), consistent with its possible other functions. Thus, the higher frequency of P286R in cancers in comparison to other

exonuclease domain changes could be explained by its exceptionally strong mutator effect and the resulting increased chances of accumulating cancer-driving mutations. Interestingly, we found the P286R variant in a tumor from a 54-year-old individual, indicating a relatively early cancer onset (the median age at diagnosis in our randomly selected group of patients was 69 with 95% confidence interval of 66-71; Table 1). Further studies could determine whether this mutation is more frequent in younger patients.

The uniquely strong mutator effect of the yeast P286R analog resembles our earlier observations with an R696W variant of Pol δ , the only extensively characterized CRC-associated Pol δ variant (17). Yeast strains expressing Pol δ -R696W had a mutation rate at least two orders of magnitude higher than any known Pol δ mutator and were generally the strongest eukaryotic mutators ever seen. Together with the present studies of Pol ϵ -P286R, this draws an interesting and unexpected picture wherein the cancer endpoint acts as an efficient selective system for the strongest mutators. Characterization of other replicative polymerase variants present in tumors in future studies will help expand and circumstantiate this view. Long-term expression of a strong mutator phenotype is believed to be disadvantageous, because it leads to an accumulation of deleterious mutations that could impede tumor growth (20). The mutagenic potential of the mutator polymerase variants, however, is buffered by the presence of the wild-type polymerases in the heterozygous tumors. Importantly, heterozygosity for the mutator alleles is still quite mutagenic (Table 2), because both wild-type and mutator enzymes contribute to replication. Thus, DNA polymerase genes constitute an uncommon class of tumor suppressors, for which loss of heterozygosity is not required to promote tumorigenesis. While limiting the genome-damaging activity of supermutator enzymes, the heterozygosity also creates opportunities for driving the genome instability by transient spikes of hypermutation due to imbalanced expression of the wild-type and mutant alleles as we discussed previously (17).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Brad Preston for discussions that led to the development of this project, the UNMC Tissue Bank personnel for help in identification of the human tissue samples appropriate for the study, Tony Mertz for yeast strains, and Elizabeth Moore and Krista Brown for technical assistance. This research was supported by NIH ES015869, CA127297, and Nebraska DHHS LB506.

Financial support: NIH ES015869 and CA127297; Nebraska DHHS LB506

References

1. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: origin and consequences. *Annu Rev Pathol.* 2010; 5:51–75. [PubMed: 19743960]
2. Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, et al. DNA polymerase ϵ and δ proofreading suppress discrete mutator and cancer phenotypes in mice. *Proc Natl Acad Sci USA.* 2009; 106:17101–4. [PubMed: 19805137]
3. Wei K, Kucherlapati R, Edelmann W. Mouse models for human DNA mismatch-repair gene defects. *Trends Mol Med.* 2002; 8:346–53. [PubMed: 12114115]

4. de la Chapelle A. Genetic predisposition to colorectal cancer. *Nat Rev Cancer*. 2004; 4:769–80. [PubMed: 15510158]
5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012; 487:330–7. [PubMed: 22810696]
6. Church DN, Briggs SE, Palles C, Domingo E, Kearsley SJ, Grimes JM, et al. DNA polymerase ϵ and δ exonuclease domain mutations in endometrial cancer. *Hum Mol Genet*. 2013; 22:2820–8. [PubMed: 23528559]
7. Cancer Genome Atlas Network. Integrated genomic characterization of endometrial carcinoma. *Nature*. 2013; 497:67–73. [PubMed: 23636398]
8. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet*. 2012; 45:136–44. [PubMed: 23263490]
9. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. *Nature*. 2012; 488:660–4. [PubMed: 22895193]
10. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. *Cancer Res*. 2013; 73:4372–82. [PubMed: 23856246]
11. Herr AJ, Ogawa M, Lawrence NA, Williams LN, Eggington JM, Singh M, et al. Mutator suppression and escape from replication error-induced extinction in yeast. *PLoS Genet*. 2011; 7:e1002282. [PubMed: 22022273]
12. Jin YH, Obert R, Burgers PM, Kunkel TA, Resnick MA, Gordenin DA. The 3'→5' exonuclease of DNA polymerase δ can substitute for the 5' flap endonuclease Rad27/Fen1 in processing Okazaki fragments and preventing genome instability. *Proc Natl Acad Sci USA*. 2001; 98:5122–7. [PubMed: 11309502]
13. Reha-Krantz LJ. DNA polymerase proofreading: Multiple roles maintain genome stability. *Biochim Biophys Acta*. 2010; 1804:1049–63. [PubMed: 19545649]
14. Shcherbakova PV, Kunkel TA. Mutator phenotypes conferred by *MLH1* overexpression and by heterozygosity for *mlh1* mutations. *Mol Cell Biol*. 1999; 19:3177–83. [PubMed: 10082584]
15. Morrison A, Bell JB, Kunkel TA, Sugino A. Eukaryotic DNA polymerase amino acid sequence required for 3'→5' exonuclease activity. *Proc Natl Acad Sci USA*. 1991; 88:9473–7. [PubMed: 1658784]
16. [Last accessed 10/5/13] NCBI SNP database links. Available from: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?geneId=5426
17. Dae DL, Mertz TM, Shcherbakova PV. A cancer-associated DNA polymerase δ variant modeled in yeast causes a catastrophic increase in genomic instability. *Proc Natl Acad Sci USA*. 2010; 107:157–62. [PubMed: 19966286]
18. Lada AG, Stepchenkova EI, Waisertreiger IS, Noskov VN, Dhar A, Eudy JD, et al. Genome-wide mutation avalanches induced in diploid yeast cells by a base analog or an APOBEC deaminase. *PLoS Genet*. 2013; 9:e1003736. [PubMed: 24039593]
19. Tran HT, Degtyareva NP, Gordenin DA, Resnick MA. Genetic factors affecting the impact of DNA polymerase δ proofreading activity on mutation avoidance in yeast. *Genetics*. 1999; 152:47–59. [PubMed: 10224242]
20. McFarland CD, Korolev KS, Kryukov GV, Sunyaev SR, Mirny LA. Impact of deleterious passenger mutations on cancer progression. *Proc Natl Acad Sci USA*. 2013; 110:2910–5. [PubMed: 23388632]

Figure 1. Mutation at codon 286 of *POLE* in a sporadic colon tumor. (A) DNA sequencing analysis of sample T-04-364 and matching normal mucosa. (B) Conservation of Pro286 in B-family DNA polymerases. Hatched boxes on the *POLE* schematic show conserved exonuclease and polymerase motifs. *Hs*, human; *Sc*, *S. cerevisiae*; *Ec*, *E. coli*. Asterisks mark Pro286 and the catalytic carboxylates affected by the *pol2-4* mutation.

Figure 2.

Yeast mimic of *POLE-P286R* is the strongest Polε mutator known. (A) Location of the known mutator mutations on the yeast Pol2 schematic. *Hatched boxes*, conserved exonuclease and polymerase motifs. (B) Rate of Can^r mutation (relative to wild-type) in haploid *pol2* mutants. Data are from Table 2 and Supplementary Table S3.

Table 1

Summary of sequence alterations in the *POLE* gene in colorectal adenocarcinoma samples from 52 patients.

Sample ID	Age at diagnosis	Tumor site	Nucleotide change ^a	Amino acid change ^a
T-07-285	33	colon		
T-99-082	36	colon		
T-00-028	42	colon		
T-01-076	47	colon		
T-08-756	48	colon		
T-05-498	53	colon		
T-04-364^b	54	colon	C857C/G	P286P/R
T-00-075	54	colon	C755C/T	A252A/V
T-02-465	56	colon		
T-01-336	58	rectum		
T-08-225	60	colon	C755C/T	A252A/V
T-98-285	60	colon		
T-03-418	61	colon		
T-00-067	62	colon	C755C/T	A252A/V
T-05-616	63	colon		
T-99-114	64	rectum		
T-09-130	65	colon		
T-01-125	66	colon	C755C/T	A252A/V
T-99-040	66	rectum		
T-04-019	67	colon		
T-04-099	67	colon		
T-09-113	67	colon	C1470C/T	synonymous
T-02-578	67	colon		
T-03-492	68	colon		
T-07-332	68	colon		
T-99-068	69	colon	C755T	A252V
T-02-052	69	colon		
T-10-274	69	colon		
T-00-102	69	colon		
T-09-366	71	colon		
T-08-387	72	colon	C755C/T	A252A/V
T-08-483	72	colon		
T-97-183	72	colon		
T-07-595	72	colon		
T-97-025	73	colon		
T-04-683	73	colon	G776G/A	R259R/H

Sample ID	Age at diagnosis	Tumor site	Nucleotide change ^a	Amino acid change ^a
T-08-400	75	colon		
T-09-675	75	colon	C755C/T	A252A/V
T-09-676	75	colon	C755C/T	A252A/V
T-10-257	75	colon		
T-05-513	76	rectum		
T-02-459	77	colon		
T-01-235	79	colon		
T-02-499	80	colon		
T-04-727	82	colon		
T-02-568	86	colon	C755C/T	A252A/V
T-08-129	86	colon		
T-08-654	87	colon		
T-97-010	88	colon		
T-97-122	88	colon		
T-08-754	88	colon		
T-01-149	96	colon	C755C/T	A252A/V

^a Nucleotides and amino acids are numbered from the first codon of *POLE* and the first amino acid, respectively.

^b Sample T-04-364 contained an additional heterozygous C→T mutation leading to Arg1826Trp substitution, although we could not determine whether it was present in *cis* or *in trans* with the codon 286 mutation. Arg1826 is a non-conserved residue away from the known functional domains, so the significance of this change is presently unclear.

Table 2

Rate of spontaneous mutation in haploid and diploid *pol2-P301R* mutants.

Ploidy	Genotype	Can ⁺ mutation		Lys ⁺ reversion		His ⁺ reversion	
		Mutation rate (×10 ⁻⁸ /a)	Fold increase	Mutation rate (×10 ⁻⁸ /a)	Fold increase	Mutation rate (×10 ⁻⁸ /a)	Fold increase
N	+	15 (10-20)	1	14 (11-16)	1	0.57 (0.42-0.75)	1
	<i>pol2-P301R</i>	2300 (1800-2800)	150	610 (450-710)	44	210 (160-250)	370
	<i>pol2-4</i>	44 (39-51)	2.9	14 (11-15)	1	3.3 (2.6-4.2)	5.8
2n	+/+	19 (16-24)	1	16 (14-18)	1	0.87 (0.62-0.92)	1
	<i>pol2-P301R</i> /+	510 (430-680)	27	29.0 (23-53)	1.8	25 (20-31)	29
	<i>pol2-4</i> /+	41 (37-46)	2.2	24 ^b (19-29)	0.8 ^b	3.3 (2.5-4.1)	3.8
	<i>pol2-P301R/pol2-P301R</i>	14000 (6900-27000)	740	4100 (2000-7500)	280	1400 (590-3100)	1600
	<i>pol2-4/pol2-4</i>	97 (73-110)	5.1	22 (18-27)	1.4	7.6 (5.7-8.6)	8.7

^aMutation rates are given as medians for at least nine cultures with 95% confidence intervals in parentheses.

^bThe *pol2-4/POL2* heterozygote contains two copies of the *lys2-InsEA14* allele. All other diploids have one copy of *lys2-InsEA14* and a non-revertible mutation at the same position of the *LYS2* gene in the homologous chromosome (Supplementary Table S2). The fold increase shown is the fold difference in the Lys⁺ reversion rate between the wild-type and *pol2-4/POL2* diploids divided by two.